Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

被引：0
|
作者：
Hui Zhang
Yingchun Xu
Peiyao Jia
Ying Zhu
Ge Zhang
Jingjia Zhang
Simeng Duan
Wei Kang
Tong Wang
Ran Jing
Jingwei Cheng
Yali Liu
Qiwen Yang
机构：
[1] Chinese Academy of Medical Science,Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College
来源：
Antimicrobial Resistance & Infection Control | / 9卷
关键词：
Ceftaroline; Ceftazidime–avibactam; Antibiotics; Surveillance; Antimicrobial resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016)
    Zhang, Hui
    Xu, Yingchun
    Jia, Peiyao
    Zhu, Ying
    Zhang, Ge
    Zhang, Jingjia
    Duan, Simeng
    Kang, Wei
    Wang, Tong
    Jing, Ran
    Cheng, Jingwei
    Liu, Yali
    Yang, Qiwen
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2020, 9 (01)
  • [2] In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
    Nichols, Wright W.
    de Jonge, Boudewijn L. M.
    Kazmierczak, Krystyna M.
    Karlowsky, James A.
    Sahm, Daniel F.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (08) : 4743 - 4749
  • [3] Global trends in nonsusceptibility rates of Escherichia coli isolates to meropenem and ceftazidime/avibactam: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-21
    Wang, Jiun-Ling
    Lai, Chih-Cheng
    Tsai, Ya-Wen
    Hsueh, Chun-Chung
    Ko, Wen-Chien
    Hsueh, Po-Ren
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (04)
  • [4] Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from US Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016
    Sader, Helio S.
    Mendes, Rodrigo E.
    Streit, Jennifer M.
    Flamm, Robert K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (09)
  • [5] Evaluation of the in vitro activity of ceftaroline, ceftazidime/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012-19
    Al-Sweih, Noura
    Jamal, Wafaa
    Mokaddas, Eiman
    Habashy, Nervana
    Kurdi, Ayman
    Mohamed, Naglaa
    JAC-ANTIMICROBIAL RESISTANCE, 2021, 3 (04):
  • [6] In vitro activity of ceftazidime-avibactam and comparators against bacterial isolates collected in South Korea as part of the ATLAS global surveillance program (2016-2018)
    Bae, In-Gyu
    Stone, Gregory G.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2022, 102 (01)
  • [7] In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)
    de Jonge, Boudewijn L. M.
    Karlowsky, James A.
    Kazmierczak, Krystyna M.
    Biedenbach, Douglas J.
    Sahm, Daniel F.
    Nichols, Wright W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3163 - 3169
  • [8] In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)
    D. Piérard
    G. G. Stone
    BMC Infectious Diseases, 21
  • [9] In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program
    Peiyao Jia
    Ying Zhu
    Hui Zhang
    Bin Cheng
    Ping Guo
    Yingchun Xu
    Qiwen Yang
    BMC Microbiology, 22
  • [10] In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program
    Jia, Peiyao
    Zhu, Ying
    Zhang, Hui
    Cheng, Bin
    Guo, Ping
    Xu, Yingchun
    Yang, Qiwen
    BMC MICROBIOLOGY, 2022, 22 (01)
12345